- Oncotelic has launched an AI-powered GMP manufacturing services platform that integrates its PDAOAI(TM) architecture, digital batch records, and intelligent robotics built with partner TechForce Robotics
- The platform targets emerging biotechs, CDMOs, cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house
- The same AI-GMP capabilities already run inside Oncotelic’s SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line
For emerging biotechnology companies, the road from promising science to clinical execution often breaks down in the same place: manufacturing. Discovery can begin in a university lab, a virtual biotech, or a lean startup, but clinical development eventually requires good manufacturing practices, regulatory documentation, batch records, quality systems, process monitoring, and scalable production. For smaller companies, building or accessing that infrastructure is slow, expensive, and operationally overwhelming.
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and high-unmet-need indications, is moving directly into that bottleneck. In June, the company launched its artificial intelligence powered GMP manufacturing services platform at the BIO International Convention 2026 in San Diego.
A Practical AI Layer for GMP Manufacturing
The platform combines Oncotelic’s proprietary PDAOAI(TM) architecture with digital manufacturing technologies and intelligent robotics developed in collaboration with TechForce Robotics, the company’s strategic robotics and automation partner. The goal is not simply to apply AI to drug discovery, but to bring it into the manufacturing workflows that determine whether a therapy moves efficiently from development toward commercialization.
The system supports electronic batch record generation and management, AI-assisted manufacturing documentation, GMP workflow digitization, quality and compliance support, process monitoring, knowledge management, and integration with intelligent robotic systems. That matters because GMP manufacturing is documentation-heavy, process-sensitive, and unforgiving. A small biotech may have strong science but limited access to experienced manufacturing teams, validated systems, or purpose-built facilities. Slow technology transfer delays clinical timelines, consumes capital, and creates execution risk at the exact point when companies need momentum.
Built for Smaller Biotechs and Advanced Therapies
Oncotelic believes the platform may be particularly valuable to emerging biotechnology companies, contract development and manufacturing organizations, cell and gene therapy developers, radiopharmaceutical manufacturers, and organizations seeking to accelerate technology transfer and scale-up.
That is a well-defined target market. Smaller drug developers often cannot justify building full GMP infrastructure in-house, yet they still need reliable manufacturing support to reach investigation of new drug filings, clinical trials, and eventual commercial readiness. An AI-enabled services model could give them access to tools normally associated with larger pharmaceutical companies, including structured documentation, operational intelligence, quality management support, and more efficient batch execution. For advanced therapeutics the need is sharper still. Cell and gene therapies, radiopharmaceuticals, sterile injectables, and nanoparticle-based drugs involve specialized handling, complex workflows, and tight compliance requirements, and digitizing portions of that process reduces friction and improves consistency.
Strategic Fit with Oncotelic’s Pipeline
The platform also aligns with Oncotelic’s own development needs. The company’s pipeline includes OT-101, a TGF-beta antisense candidate, along with programs spanning oncology, rare pediatric indications, COVID-19 and zoonoses, Parkinson’s disease, and sexual dysfunction. Its Deciparticle(TM) nanomedicine platform includes SAPU003, a clinical-stage intravenous everolimus program currently in a Phase 1b study.
This is where the story gains weight. Oncotelic did not design the AI-GMP stack in the abstract. Its SAPU San Diego site is a GMP-certified, ISO 5 manufacturing facility whose quality control and assurance are already run through an AI-driven data management and quality management system, with capacity to support multiple new INDs per year. In other words, the company built AI-enabled GMP for its own clinical-stage execution first, then packaged those capabilities for outside developers facing the same constraints. Manufacturing is not an outside service line bolted onto the business. It is core infrastructure Oncotelic depends on.
A Potential New Revenue Channel
For investors, the platform adds a second layer to the Oncotelic story. The company remains a clinical-stage biotech, but the AI-GMP platform could extend its role into enabling infrastructure for other drug developers. If adopted commercially, that creates a services-based revenue opportunity while strengthening Oncotelic’s internal development engine. Combined with TechForce Robotics’ automation capabilities, the launch reflects a broader industry shift toward intelligent manufacturing systems that reduce manual workload and tighten compliance discipline. For small biotechs, the promise is straightforward: manufacturing support without building everything from scratch. For Oncotelic, the strategy is to turn one of biotech’s hardest operational problems into both a strategic advantage and a business line.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
